Concise answers when you need the essentials, with deeper clinical context and transparent source links when the decision needs more scrutiny.
Search by active ingredient or familiar medicine name.
Miconazole nitrate is an imidazole antifungal applied to the skin. The selected cream and spray-powder products are licensed for athlete’s foot; the spray powder can also help prevent it.
Midazolam is a short-acting benzodiazepine that causes sedation, reduces anxiety and can impair memory after it is given. Selected products are used around procedures, during anaesthesia and for intensive-care sedation.
Midazolam hydrochloride is a short-acting benzodiazepine that reduces brain activity. Oromucosal midazolam is used as rescue treatment for prolonged convulsive seizures, while injectable products are used for procedural sedation, anaesthesia and intensive-care sedation.
Midazolam maleate is a short-acting benzodiazepine with anticonvulsant and sedative effects. The selected Epistatus oromucosal product is a rescue treatment for prolonged acute convulsive seizures in people aged 3 months and over with diagnosed epilepsy.
Midodrine hydrochloride is a prescription-only vasopressor that tightens peripheral blood vessels and raises blood pressure. It is usually used in adults with severe orthostatic hypotension caused by autonomic dysfunction when reversible causes have been addressed and other treatments are inadequate.
Midostaurin is a protein kinase inhibitor used in adults with certain blood cancers. In FLT3 mutation-positive acute myeloid leukaemia it is used alongside chemotherapy and may later be used alone; it is also used alone for advanced forms of systemic mastocytosis.
Mifamurtide is a liposomal immunostimulant used as part of specialist osteosarcoma care. It is licensed for children, adolescents and young adults with high-grade, resectable osteosarcoma that has not spread, after complete surgical removal and alongside postoperative chemotherapy.
Mifepristone and misoprostol are used together to end an early pregnancy without surgery. Mifepristone blocks progesterone, while misoprostol opens the cervix and causes the womb to contract.
Migalastat hydrochloride is an oral pharmacological chaperone for Fabry disease in eligible adults and adolescents with an amenable GLA gene mutation. It stabilises certain faulty forms of alpha-galactosidase A so the enzyme can work within cells.
Miglustat is an oral substrate-reduction treatment for certain rare inherited metabolic disorders. In the selected UK product, it is used for mild to moderate type 1 Gaucher disease when enzyme replacement therapy is unsuitable, and for progressive neurological manifestations of Niemann–Pick type C disease.
Milrinone is an intravenous phosphodiesterase-3 inhibitor that strengthens heart contraction and widens blood vessels. It is used in hospital for short-term support in severe or acute heart failure, including low-output states after cardiac surgery.
Minocycline hydrochloride is a tetracycline antibiotic that limits bacterial growth. The selected modified-release capsules are licensed for acne, although NHS England advises against routinely starting minocycline for acne in primary care because of its safety profile.
Minoxidil is available as scalp preparations for pattern hair loss and as tablets for severe hypertension. Oral minoxidil for hair loss is not UK licensed, although some specialist services use it off-label.
Mirabegron is a beta-3 adrenoceptor agonist that relaxes the bladder during urine storage. It treats urgency, urinary frequency and urgency incontinence in adults with overactive bladder. The selected product is also licensed for neurogenic detrusor overactivity in people aged 3 to under 18 years.
Mirikizumab is a biological treatment that blocks interleukin-23, a protein involved in inflammation. It is licensed for adults with moderately to severely active ulcerative colitis or Crohn’s disease when other treatment has not worked adequately, has stopped working or cannot be tolerated.
Mirtazapine is a prescription antidepressant used mainly to treat episodes of major depression in adults. It affects noradrenaline and serotonin signalling and can cause sleepiness, particularly when treatment begins.
Misoprostol is a synthetic prostaglandin that softens the cervix and stimulates uterine contractions. The selected product is licensed for hospital induction of labour; it also has specialist uses in miscarriage and abortion care outside this product licence.
Mitomycin is a cytotoxic antibiotic that damages cancer-cell DNA. In specialist cancer care it may be given into a vein for selected advanced cancers or placed directly into the bladder to reduce recurrence after tumour removal.
Mitotane is an antineoplastic treatment that targets the adrenal cortex. In the UK, it is licensed to treat symptoms of advanced adrenocortical carcinoma that cannot be removed surgically, has spread or has returned.
Mitoxantrone hydrochloride is a cytotoxic anthracenedione that damages DNA and prevents cancer cells from multiplying. It is used for selected blood cancers, metastatic breast cancer and palliative treatment of advanced prostate cancer.
Mivacurium chloride is a short-acting neuromuscular blocker used with general anaesthesia. It temporarily relaxes skeletal and breathing muscles to support tracheal intubation and mechanical ventilation during procedures.
Moclobemide is an antidepressant that reversibly inhibits monoamine oxidase type A. Selected products are licensed for major depression; Manerix is also licensed for social phobia.
Modafinil is a prescription-only wakefulness-promoting treatment for excessive sleepiness in adults with narcolepsy, with or without cataplexy. It does not replace adequate sleep and may not completely remove sleepiness.
Mogamulizumab is a monoclonal antibody that targets CCR4 on certain T cells. It is used for adults with mycosis fungoides or Sézary syndrome after previous systemic treatment.
Molnupiravir is a direct-acting antiviral used to treat mild to moderate COVID-19. Its UK licence covers adults with a positive SARS-CoV-2 test and at least one risk factor for severe illness.
Momelotinib is an oral protein kinase inhibitor used by specialist cancer teams. It treats an enlarged spleen and other disease-related symptoms in adults with certain forms of myelofibrosis and moderate to severe anaemia.
This prescription nasal spray combines olopatadine, an antihistamine, with mometasone, a corticosteroid. It is used to relieve moderate to severe nasal symptoms of allergic rhinitis in adults and adolescents aged 12 years and over.
Moroctocog alfa is a recombinant form of clotting factor VIII. It replaces deficient factor VIII to prevent or control bleeding in people with haemophilia A.
Mosunetuzumab is a bispecific monoclonal antibody that helps T cells recognise and destroy abnormal B cells. It is licensed on its own for adults with follicular lymphoma that has returned or not responded after at least two previous systemic treatments.
Moxifloxacin is a fluoroquinolone antibiotic that kills susceptible bacteria. Selected tablets treat certain infections when commonly recommended antibiotics are inappropriate; eye drops treat purulent bacterial conjunctivitis.
Moxonidine is a centrally acting antihypertensive licensed in the selected UK product for mild to moderate essential hypertension. It lowers blood pressure by reducing sympathetic nerve activity.
This topical combination contains an anti-inflammatory heparinoid-like substance and salicylic acid. It is used for local symptomatic relief of muscle pain and stiffness, sprains, strains and pain from rheumatic or non-serious arthritic conditions.
Mupirocin is a topical antibiotic used on the skin or inside the nose for certain local bacterial infections, infected minor wounds, or nasal carriage of staphylococci including MRSA.
Mupirocin calcium is a locally acting antibiotic nasal ointment used to clear staphylococcal bacteria, including susceptible MRSA, carried inside the nose.
Mycophenolate mofetil is an immunosuppressant that reduces the activity of immune cells called lymphocytes. Its licensed role is to help prevent rejection after a kidney, heart or liver transplant, alongside other immunosuppressants.
An intravenous immunosuppressant converted to mycophenolic acid, used with ciclosporin and corticosteroids to prevent acute rejection after adult kidney or liver transplantation.
An immunosuppressant that reduces immune-cell activity involved in transplant rejection. The selected gastro-resistant tablet is licensed with other immunosuppressants to help prevent acute rejection after an adult kidney transplant.
Nabilone is a synthetic cannabinoid capsule with effects similar to THC. It is licensed for adults with nausea and vomiting caused by cancer chemotherapy when conventional anti-sickness treatments have not worked adequately.
Nabumetone is a prescription non-steroidal anti-inflammatory drug (NSAID) used to reduce pain and inflammation in osteoarthritis and rheumatoid arthritis.
Nadolol is a long-acting, non-selective beta blocker. It is licensed to manage angina, high blood pressure and fast abnormal heart rhythms, prevent migraine, and control symptoms of thyrotoxicosis.
Nafarelin acetate is a gonadotrophin-releasing hormone (GnRH) agonist nasal spray. It lowers ovarian hormone production and is licensed for endometriosis and specialist-supervised IVF programmes.
Naldemedine tosylate is a peripherally acting opioid-receptor antagonist used to treat constipation caused by opioid pain medicines. In the UK, it is licensed for adults who have previously been treated with a laxative.
Nalmefene hydrochloride dihydrate is an opioid-system modulator used to help some adults with alcohol dependence reduce alcohol consumption. It is for people who remain at high drinking risk, do not have physical withdrawal symptoms and do not need immediate detoxification, alongside continuing psychosocial support.
Naloxegol oxalate is a peripherally acting opioid-receptor antagonist for opioid-induced constipation in adults when laxatives have not worked adequately. It is designed to preserve opioid pain relief in the central nervous system.
Naloxone hydrochloride is an opioid antagonist that rapidly blocks opioid effects. It is usually used in emergencies to restore breathing and consciousness after suspected opioid overdose, or by clinicians to reverse unwanted opioid effects.
This prolonged-release combination contains oxycodone, a strong opioid painkiller, and naloxone, which mainly blocks opioid effects within the bowel. It is licensed for adults with severe pain that can only be adequately managed with opioid analgesics, while helping counter opioid-induced constipation.
Naloxone hydrochloride dihydrate temporarily reverses dangerous opioid effects, particularly slowed or stopped breathing and reduced consciousness. It supports emergency resuscitation but does not replace an ambulance, airway support or continued monitoring.
This prolonged-release combination contains oxycodone, an opioid that relieves severe pain, and naloxone, which mainly acts in the bowel to reduce opioid-related bowel dysfunction. In adults, the selected UK product is licensed for severe pain requiring an opioid and, under specialist supervision, severe idiopathic restless legs syndrome when dopaminergic treatment has failed.
Naltrexone hydrochloride is an opioid-receptor antagonist used alongside psychological and recovery support. The selected UK product is licensed to reduce alcohol craving and help prevent relapse in alcohol dependence; oral naltrexone is also used after opioid detoxification.
These eye drops combine naphazoline, an ocular decongestant, with distilled witch hazel, an astringent. They are licensed for temporary relief of redness caused by minor eye irritation.
Naproxen is a non-steroidal anti-inflammatory drug (NSAID) that reduces pain and inflammation. UK licences vary by product and include inflammatory joint disease, gout, period pain and musculoskeletal pain or injury.
Combines an anti-inflammatory painkiller with a triptan for the headache phase of migraine with or without aura in adults when either component alone has been insufficient. It does not prevent migraine.
Naratriptan is a triptan used to treat an acute migraine attack with or without aura. It acts after the headache has begun and is not intended to prevent attacks.
Natalizumab is a monoclonal antibody and disease-modifying treatment for adults with highly active relapsing-remitting multiple sclerosis. It reduces inflammatory immune-cell movement into the brain and spinal cord but does not cure multiple sclerosis.
Nateglinide is a rapid, short-acting insulin-releasing treatment for type 2 diabetes. In its selected UK product information, it is used with metformin when metformin alone has not controlled blood glucose adequately.
Nebivolol is a selective beta blocker that slows the heart and helps blood vessels relax. The selected product is licensed for essential hypertension and, alongside standard therapy, stable mild or moderate chronic heart failure in people aged 70 years or over.
Nebivolol hydrochloride is a selective beta blocker that slows the heart and also helps blood vessels relax. It is licensed for essential hypertension and, alongside standard therapy, stable mild or moderate chronic heart failure in people aged 70 years or older.
Nefopam hydrochloride is a prescription-only, non-opioid painkiller that acts in the central nervous system. It is used to relieve acute or chronic pain, including pain after surgery or injury, dental or musculoskeletal pain, and cancer pain.
Nelarabine is a cytotoxic purine analogue used against certain cancers of immature T cells. In the UK, it is licensed for T-cell acute lymphoblastic leukaemia or T-cell lymphoblastic lymphoma that has not responded to, or has returned after, at least two chemotherapy regimens.
Neostigmine methylsulfate is a reversible cholinesterase inhibitor that strengthens acetylcholine signalling between nerves and muscles. The selected injection is mainly used for myasthenia gravis and to reverse certain muscle relaxants after surgery.